Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Pentylenetetrazole (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Acronyms ARISE2
- Sponsors Balance Therapeutics
- 28 Apr 2020 Planned End Date changed from 1 Dec 2019 to 28 May 2020.
- 28 Apr 2020 Planned primary completion date changed from 1 Sep 2019 to 1 May 2020.
- 28 Apr 2020 Status changed from recruiting to active, no longer recruiting.